SecBot SecBot
6-K ·Filed Jun 25, 2026

CLLS

Cellectis S.A.
NEUTRAL
Impact 4/10
Horizonweeks Processed4mo ago SEC0001193125-26-282865
Notable filing: 6-K
Actionable Insight • Neutral

The meeting's approval of broad capital increase authorities (including an ATM program) is a standing dilution risk that may pressure the stock over the medium term, as the company can issue shares without shareholder vote. Monitor for any actual drawdown on the ATM facility or placement announcements as a bearish catalyst.

DirectionNeutral
Confidencemedium
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
CLLS ▼ -46.64% at T+60d
NEUTRAL call -46.64% · α vs SPY -52.75% · entry $2.83 → $1.51
Entry = T+0 close
Jun 25, 2026
via day close
T+1d
+3.89%
call +3.89% · α +2.24%
$2.94
settled 4mo ago
T+5d
+16.61%
call +16.61% · α +14.44%
$3.30
settled 4mo ago
T+20d
-2.12%
call -2.12% · α -3.38%
$2.77
settled 3mo ago
T+60d
-46.64%
call -46.64% · α -52.75%
$1.51
settled 5w ago

Price Chart

Loading chart...

Executive Summary

Cellectis S.A. held its Combined General Meeting of Shareholders on June 25, 2026, and all 30 proposed resolutions were carried. Key approvals include the 2025 annual and consolidated financial statements, renewal of four board members, share buyback authorization, cancellation of repurchased shares, and multiple delegations to the Board to increase share capital—including an ATM program and issuances without preferential subscription rights to designated investors in the health/biotech sector. The near-97.8% approval of capital increase delegations signals a clear mandate for potential future dilution, though no immediate offering is announced.

Key Facts

  • All 30 resolutions carried at the June 25, 2026 Combined General Meeting; quorum was 55.84% of share capital.
  • Resolutions 13-19 and 21-23 authorize the Board to issue shares without preferential subscription rights to specific investor categories (health/biotech, banks, development institutions).
  • Resolution 18 specifically approves an At-the-Market (ATM) equity program on the U.S. market.
  • Resolution 19 caps non-preferred issuances at 30% of capital for specifically designated persons.
  • Resolutions 26 and 27 authorize option grants and free share allocations to employees/officers, waiving subscription rights.
  • Resolution 10 authorizes share buybacks; Resolution 11 authorizes cancellation of repurchased shares.
  • Resolution 30 (capital increase reserved for employee savings plan) passed with only 14.81% support (85.19% against), but still carried.

Financial Impact

No immediate capital raise announced. The authorized but unexercised capital increase delegations represent potential future dilution up to 30% of current capital under Resolution 19, plus additional ATM capacity. No dollar amounts for any offering disclosed.

dilutionshare count

Risk Factors

  • Potential dilutive equity issuance under newly authorized ATM program or other placements to fund operations
  • High percentage of against votes (85.19%) on employee share plan (Resolution 30) indicates some shareholder pushback on dilution-related governance

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-282865
Document: ccls_6-k_agm_vote_result.htm0001193125-26-282865
Document: 0001193125-26-282865-index-headers.html0001193125-26-282865
Document: 0001193125-26-282865-index.html0001193125-26-282865
Document: 0001193125-26-282865.txt0001193125-26-282865
14 reports for CLLS
Performance horizon
40% Hit rate @ T+60 2 of 5 directional calls Went positive at some point 4 of 6 best @ T+20▲ +35.52%Sep 14, 2026
Filters
Rows
Reports for CLLS — sortable, filterable
TypeNow
Sep 14, 2026
6w ago
6-K
BEARISH ★ 6/10
$1.83awaiting T+60—$0.9670 (+47.16%)
Sep 11, 2026
6w ago
Press Release
NEUTRAL ★ 2/10
$1.83awaiting T+60—$0.9670 (−47.16%)
Aug 6, 2026
11w ago
Press Release
MIXED ★ 5/10
$2.84awaiting T+60—$0.9670 (−65.89%)
Jun 29, 2026
17w ago
Court Ruling
BULLISH ★ 6/10
$3.00 $1.43▼ −52.33%▼ −55.32%$0.9670 (−67.77%)
Jun 25, 2026
17w ago
6-K
NEUTRAL ★ 2/10
$2.83 $1.51▼ −46.64%▼ −52.75%$0.9670 (−65.83%)
Jun 25, 2026
17w ago
6-K
NEUTRAL ★ 4/10
$2.83 $1.51▼ −46.64%▼ −52.75%$0.9670 (−65.83%)
Jun 11, 2026
19w ago
Press Release
BULLISH ★ 7/10
$3.09 $3.24▲ +4.85%▲ +0.46%$0.9670 (−68.71%)
Jun 9, 2026
19w ago
6-K
BULLISH ★ 7/10
$3.18 $3.32▲ +4.40%▼ −2.18%$0.9670 (−69.59%)
May 12, 2026
23w ago
6-K
NEUTRAL ★ 3/10
$3.96 $2.69▼ −32.07%▼ −36.45%$0.9670 (−75.58%)
May 4, 2026
25w ago
6-K
NEUTRAL ★ 2/10
$3.76 $2.85▼ −24.20%▼ −26.94%$0.9670 (−74.28%)
Showing 10 of 14

US Market Status

Market Closed — Opens in 7h 32m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 25, 2026